国医科技递表港交所 为中国最大的第三方SPD解决方案提供商

Core Viewpoint - Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") has submitted a listing application to the Hong Kong Stock Exchange, with Haitong International Capital Limited as its sole sponsor. Guoyi Technology is a leader in China's third-party SPD (Supply, Processing, and Distribution) solutions market, holding a market share of 29.2% based on projected 2024 revenue, and is the first third-party SPD solution provider in China [1][3]. Company Overview - SPD refers to an innovative supply chain model aimed at optimizing hospitals' management of medical supplies. It includes procurement management, inventory handling, and distribution management within hospitals. Traditional supply chain models rely heavily on manual operations and limited information sharing [3]. - Guoyi Technology's SPD solutions consist of three core components: SPD software systems, intelligent hardware, and professional services. These solutions help hospitals reduce operational costs and improve supply management efficiency [3]. - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including three of the eight A++ hospitals that have adopted SPD solutions [3]. Financial Information - Revenue for the years ending December 31 and September 30 is as follows: - 2023: approximately RMB 248.2 million - 2024: approximately RMB 377.9 million - 2025 (as of September 30): approximately RMB 306 million [7][8]. - The total profit and comprehensive income for the same periods are: - 2023: approximately RMB 12.3 million - 2024: approximately RMB 57.6 million - 2025 (as of September 30): approximately RMB 43.2 million [9]. - Gross profit margins for the respective years are: - 2023: 37.1% - 2024: 41.8% - 2025 (as of September 30): 38.8% [10]. Industry Overview - The SPD solutions market in China is projected to grow significantly, with the total market size increasing from RMB 18.4 billion in 2019 to RMB 181.5 billion by 2024, reflecting a compound annual growth rate (CAGR) of 58.1%. By 2029, the market is expected to reach RMB 1,057.4 billion, with a CAGR of 42.3% from 2024 to 2029 [11][12]. - The total transaction value of medical consumables through SPD solutions is expected to grow from RMB 15.9 billion in 2019 to RMB 151.3 billion by 2024, with a CAGR of 56.9%. By 2029, it is projected to reach RMB 724.9 billion [11][12]. - The third-party SPD solutions market is expected to grow from RMB 1 billion in 2019 to RMB 11 billion by 2024, with a CAGR of 75.7%. By 2029, it is projected to reach RMB 9.6 billion, with a CAGR of 53.3% from 2024 to 2029 [14][15].